



VOLUME 2001, ARTICLE 3A
JULY 2001

Neurology and Clinical Neurophysiology

ISSN 1526-8748. MIT Press Journals, Five Cambridge Center, Cambridge, MA 02142, USA; tel.: (617) 253-2889; fax: (617) 577-1545; *journals-orders@mit.edu*, *journals-info@mit.edu*. Published one article at a time in html and PDF source form on the Internet. For more information and other articles see:

- <http://mitpress.mit.edu/jrnls-catalog/cont-neuro.html>

©2001 American Academy of Clinical Neurophysiology. Subscribers are licensed to use journal articles in a variety of ways, limited only as required to insure fair attribution to authors and the *Journal*, and to prohibit use in a competing commercial product. See the *Journal's* World Wide Web site for further details. Address inquiries to the Subsidiary Rights Manager, MIT Press Journals; (617) 253-2864; *journals-rights@mit.edu*.



The MIT Press

JENS D. ROLLNIK, MD*,
KAI WOHLFARTH, MD*,
REINHARD DENGLE, MD*,
AND HANS BIGALKE, MD*

From *Department of Neurology
and Clinical Neurophysiology,

†Department of Pharmacology and
Toxicology, Medical School of
Hannover, Hannover, Germany.

Neutralizing Botulinum Toxin Type A Antibodies: Clinical Observations in Patients with Cervical Dystonia

■ Neutralization of antibodies poses a problem for a substantial number of cervical dystonia (CD) patients treated with botulinum toxin type A (BoNT/A). Presence of these antibodies may lead to a secondary nonresponse to BoNT/A treatment. In this study, we compared 6 antibody-positive (Ab+) with 12 antibody-negative (Ab-) CD patients treated with BoNT/A (Dysport®) and matched for duration of treatment, number of BoNT/A injections, and severity of clinical symptoms. The two groups differed in cumulative BoNT/A dose (Ab+, 5984 mouse units [MU], SD = 3151 MU; Ab-, 3143 MU, SD = 1294 MU; $P < .05$). In addition, Ab+ patients were significantly younger (Ab+ mean age = 41.3 y, SD = 5.9 y; Ab- mean age = 56.8 y, SD = 15.3 y; $P < .05$). In order to avoid formation of neutralizing antibodies, doses of BoNT/A should be kept as low as possible. The risk of antibody formation seems to be higher in younger patients. ■

Keywords: botulinum toxin type A (BoNT/A), antibodies, cervical dystonia (CD), therapy

Local injections of botulinum toxin type A (BoNT/A) may be used in the treatment of diseases associated with increased muscle tension (eg, dystonia; Tsui et al, 1985; Tsui et al, 1986; Greene et al, 1990), spasticity (Snow et al, 1990), involuntary cocontractions (Rollnik, Hierner, et al, 2000), and pain syndromes like tension-type headaches (Rollnik, Tanneberger, et al, 2000).

Therapeutic doses of BoNT/A are usually too low to stimulate the immune system. Nevertheless, formation of BoNT/A antibodies may be observed in a substantial number of patients (Anderson et al, 1992; Greene and Fahn, 1992; Göschel et al, 1997). This immune response may result in a secondary nonresponse to BoNT/A and necessitate termination of treatment (Göschel et al, 1997). Nonresponse can be defined as a primary or secondary therapeutic failure (clinically defined) to BoNT/A treatment (Dressler, 1995). Specific antibodies pose a problem for 3% of patients with cervical dystonia (CD) after 15 months of therapy (Anderson et al, 1992) and for 8% after 20 months of therapy (Greene and Fahn, 1992). We must mention, however, that marginal titers of neutralizing antibodies may also be observed among responders (Göschel et al, 1997). In addition, nonneutralizing antibodies do not affect the therapeutic outcome (Göschel et al, 1997). Some patients may revert from immunoresistance (Ab+) to antibody-negative (Ab-) status (Sankhla et al, 1998). Nevertheless, repeated injections can boost antibody formation in this subgroup of patients (Sankhla et al, 1998).

The conditions under which BoNT/A antibodies may form are still a matter of discussion. Siatkowski et al (1993) found no significant differences between Ab+ and Ab- patients with respect to duration of treatment, number of injections, or cumulative dose of BoNT/A. These findings might be explained by a huge variation in data from a heterogeneous group of patients (blepharospasm, facial hemispasm, CD). Nevertheless, a few studies support the hypothesis that cumulative BoNT/A dose is a major factor in the formation of neutralizing antibodies: Low-dose treatment of CD does not induce antibody formation (Brans et al, 1995). Our recent investigation involving 115 patients treated with low-dose BoNT/A (Rollnik, Matzke, et al, 2000) supports this finding.

SUBJECTS AND METHODS

We studied 6 Ab+ CD patients exhibiting a secondary nonresponse to BoNT/A (Dysport®) treatment. Mean age was 41.3 years (SD, 5.9 y). Secondary nonresponse was defined as the first ineffective treatment (at which point in time an antibody assay was performed). These Ab+ patients were compared with 12 Ab- patients (mean age, 56.8 y; SD, 15.3 y) matched for severity of clinical symptoms, duration of treatment, and number of treatments (Table 1).

Address correspondence and reprint requests to Jens D. Rollnik, MD, Department of Neurology and Clinical Neurophysiology, Medical School of Hannover, D-30623 Hannover, Germany (e-mail: rollnik.jens@mh-hannover.de).

© 2001 American Academy of Clinical Neurophysiology

Table 1 Group Characteristics

| | BoNT/A Antibody Positive (Ab+) | BoNT/A Antibody Negative (Ab-) | Statistic |
|---|-----------------------------------|-----------------------------------|-----------|
| N | 6 | 12 | |
| Female/male (n) | 3/3 | 5/7 | |
| Age (y) | 41.3 (5.9) | 56.8 (15.3) | $P < .05$ |
| Duration of treatment (mo) | 31.5 (10.2) | 29.6 (9.7) | NS |
| No. treatments until nonresponse | 11.7 (4.9) | 8.8 (3.7) | NS |
| Cumulative BoNT/A (Dysport®) dose until nonresponse (MU) | 5984 (3151) | 3125 (2126) | $P < .05$ |

Data are means (SDs), except where noted otherwise. BoNT/A = botulinum toxin type A; NS = not significant; MU = mouse units.

Neutralizing BoNT/A antibodies were detected and quantified using an in vitro toxin-neutralizing assay based on a nerve-muscle preparation (Göschel et al, 1997). Statistical analyses used *t* tests for independent samples (Ab+ vs Ab-) and bivariate Pearson correlations.

RESULTS

In Ab+ patients, secondary nonresponse occurred after an average of 11.7 treatments (SD, 4.9 treatments) over an average of 31.5 months (SD, 10.2 mo). Mean antibody titer in the first assay was 2.36 mU per mL (SD, 4.27 mU/mL; range, 0.30–10.00 mU/mL). Cumulative BoNT/A dose until secondary nonresponse was 5984 mouse units (MU; SD, 3151 MU). (See Table 1.)

In Ab- patients, cumulative BoNT/A dose after 8.8 injections (SD, 3.7 injections) over 29.6 months (SD, 9.7 mo) was 3143 MU (SD, 2125 MU).

Ab+ and Ab- patients differed in cumulative BoNT/A dose ($t = -2.31$, $df = 16$, $P = .037$) and age (Ab+ mean age = 41.3 y, SD = 5.9 y; Ab- mean age = 56.8 y, SD = 15.3 y; $P = .032$).

When neutralizing antibodies were detected, BoNT/A therapy was stopped for approximately 6 months. After this interruption, patients profited from an average of 2.7 additional treatments (SD, 2.0 treatments; range, 1–6 treatments) before a definite nonresponse occurred. After an average of 9.6 months (SD, 5.5 mo), a second antibody assay was performed. This assay showed BoNT/A antibody titer of 3.45 mU per mL (SD, 4.24 mU/mL; range, 0.40–10.00 mU/mL). Increase in antibody titer correlated significantly with the BoNT/A dose given between the first and second assays ($r = .97$, $df = 5$, $P = .006$), which suggests a booster effect. Mean BoNT/A dose before the second assay was 578 MU (SD, 678 MU; range, 115–1750 MU). In 1 case, Botox® was used instead of Dysport; with Botox, the titer increase was also considerable (Fig. 1).

CONCLUSIONS

Formation of neutralizing BoNT/A antibodies poses a problem for 3% to 8% of patients with CD after 15 to 20 months of treatment with regular doses of BoNT/A (Anderson et al, 1992; Greene and Fahn, 1992). Presence of these antibodies may lead to a secondary nonresponse to BoNT/A application, necessitating termination of treatment (Göschel et al, 1997). The conditions leading to antibody formation, however, are still a matter of discussion. Some authors (eg, Siatkowski et al, 1993) have hypothesized that the cumulative BoNT/A dose is not of major importance; others (eg, Brans et al, 1995; Rollnik, Matzke, et al, 2000) have indicated that low-dose treatment may be a successful strategy in the prevention of antibody formation.




Figure 1. Titer of neutralizing botulinum toxin type A (BoNT/A) antibodies (mU/mL) during treatment with Dysport® and Botox®. Change in medication did not lead to decrease in titer. Dysport and Botox had similar booster effects. Definite nonresponse occurred in month 16 after application of 375 mouse units (MU) Botox.

In the present study, we investigated which factors might contribute to antibody formation. Of cumulative dose, duration of treatment, and number of treatments, only cumulative dose was a significant predictor of antibody formation. In addition, Ab+ patients were significantly younger than Ab- controls. This finding could be explained by the fact that immune function declines with age (Lesourd and Mazari, 1999). Therefore, younger patients might have a higher risk for forming neutralizing antibodies.

In addition, our results suggest that Ab+ patients may profit from a treatment break and then approximately 3 additional injections (Sankhla et al, 1998). Nevertheless, repeating BoNT/A injections creates a vicious circle. From our experience, we know that therapy fails for these patients after 2 or 3 treatments. A change in medication (from Dysport to Botox, or vice versa) is useless; only a change in neurotoxin subtype (to BoNT/B or BoNT/F) might be promising (Sankhla et al, 1998).

In line with other studies, we recommend that the BoNT/A dose should be as low as possible in order to prevent formation of neutralizing antibodies (Brans et al, 1995; Rollnik, Matzke, et al, 2000), as cumulative dose does seem to play a major role. After a nonresponse to BoNT/A treatment, an antibody assay should be performed in order to identify Ab+ patients. When neutralizing antibodies begin forming, some patients may profit from a break of approximately 6 months and then approximately 3 additional BoNT/A treatments.

Further studies on neutralizing BoNT/A antibodies are strongly encouraged.

REFERENCES

- Anderson TJ, Rivest J, Stell R, et al. Botulinum toxin treatment of spasmodic torticollis. *J Roy Soc Med*. 1992;85:524–529.
- Brans JW, de Boer JP, Aramideh M, et al. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. *J Neurology*. 1995;8:529–534.
- Dressler D. *Botulinum-Toxin-Therapie*. Stuttgart, Germany: Thieme; 1995.
- Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies—therapeutic consequences. *Exp Neurol*. 1997;147(1):96–102.
- Greene P, Fahn S. Development of antibodies to botulinum toxin type A in torticollis patients treated with botulinum toxin injection. *Mov Disord*. 1992;7(suppl 1):134.
- Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. *Neurology*. 1990;40:1213–1218.
- Lesourd B, Mazari L. Nutrition and immunity in the elderly. *Proc Nutr*. 1999;58:685–695.
- Rollnik JD, Hierner R, Schubert M, et al. Botulinum toxin treatment of co-contractions after birth-related brachial plexus lesions. *Neurology*. 2000;55(1):112–114.
- Rollnik JD, Matzke M, Wohlfarth K, et al. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance: an open label study. *Eur Neurol*. 2000;43(1):9–12.
- Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A—a double-blind placebo-controlled study. *Headache*. 2000;40:300–305.
- Sankhla, C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. *Mov Disord*. 1998;13(1):150–154.
- Siatkowski RM, Tyutyunikov A, Biglan AW, et al. Serum antibody production to botulinum A toxin. *Ophthalmology*. 1993;100:1861–1866.
- Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. *Neurology*. 1990;28:512–515.
- Tsui JK, Eisen A, Mak E, et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. *Can J Neurol Sci*. 1985;12:314–316.
- Tsui JKC, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. *Lancet*. 1986;2:247.

EDITOR

Keith H. Chiappa, M.D.

ASSOCIATE EDITOR

Didier Cros, M.D.

ELECTRONIC MAIL

chiappa@helix.mgh.harvard.edu

Neurology and Clinical Neurophysiology is a peer-reviewed and electronically published scholarly journal that covers a broad scope of topics encompassing clinical and basic topics of human neurology, neurosciences and related fields.

EDITORIAL BOARD

Robert Ackerman
Massachusetts General Hospital, Boston

Barry Arnason
University of Chicago

Flint Beal
Massachusetts General Hospital, Boston

James Bernat
*Dartmouth-Hitchcock Medical Center,
New Hampshire*

Julien Bogousslavsky
CHU Vaudois, Lausanne

Robert Brown
Massachusetts General Hospital, Boston

David Burke
*Prince of Wales Medical Research Institute,
Sydney*

David Caplan
Massachusetts General Hospital, Boston

Gregory Cascino
Mayo Clinic, Rochester

Phillip Chance
*The Children's Hospital of Philadelphia,
Philadelphia*

Thomas Chase
NINDS, National Institutes of Health, Bethesda

David Cornblath
Johns Hopkins Hospital, Baltimore

F. Michael Cutrer
Massachusetts General Hospital, Boston

David Dawson
Brockton VA Medical Center, Massachusetts

Paul Delwaide
Hôpital de la Citadelle, Liege

John Donoghue
Brown University, Providence

Richard Frith
Auckland Hospital, New Zealand

Myron Ginsberg
University of Miami School of Medicine

Douglas Goodin
University of California, San Francisco

James Grotta
University of Texas Medical School, Houston

James Gusella
Massachusetts General Hospital, Boston

John Halperin
*North Shore University Hospital / Cornell
University Medical College*

Stephen Hauser
University of California, San Francisco

E. Tessa Hedley-White
Massachusetts General Hospital, Boston

Kenneth Heilman
University of Florida, Gainesville

Daniel Hoch
Massachusetts General Hospital, Boston

Fred Hochberg
Massachusetts General Hospital, Boston

John Hoffman
Emory University, Atlanta

Gregory Holmes
Children's Hospital Boston

Bruce Jenkins
Massachusetts General Hospital, Boston

Ryuji Kaji
Kyoto University Hospital

Carlos Kase
Boston University School of Medicine, Boston

J. Philip Kistler
Massachusetts General Hospital, Boston

Jean-Marc Léger
La Salpêtrière, Paris

Simmons Lessell
Massachusetts Eye and Ear Infirmary, Boston

Ronald Lesser
Johns Hopkins Hospital, Baltimore

David Levine
New York University Medical Center

Ira Lott
University of California, Irvine

Phillip Low
Mayo Clinic, Rochester

Richard Macdonell
Austin Hospital, Victoria, Australia

Joseph Masdeu
St. Vincent's Hospital, New York

Kerry R. Mills
Radcliffe Infirmary, Oxford

José Ochoa
Good Samaritan Hospital, Portland

Barry Oken
Oregon Health Sciences University, Portland

John Penney
Massachusetts General Hospital, Boston

Karlheinz Reiners
*Bayerische Julius-Maximilians-Universität,
Würzburg*

Allen Roses
Duke University Medical Center, Durham

Thomas Sabin
Boston City Hospital, Boston

Raman Sankar
University of California at Los Angeles

Joan Santamaria
Hospital Clinic Provincial de Barcelona

Kenneth Tyler
*University of Colorado Health Science Center,
Denver*

Francois Viallet
CH Aix-en-Provence

Joseph Volpe
Children's Hospital, Boston

Michael Wall
University of Iowa, Iowa City

Stephen Waxman
Yale University, New Haven

Wigbert Wiederholt
University of California, San Diego

Eelco Wijdicks
Mayo Clinic, Rochester

Clayton Wiley
University of California, San Diego

Anthony Windebank
Mayo Clinic, Rochester

Shirley Wray
Massachusetts General Hospital, Boston

Anne Young
Massachusetts General Hospital, Boston

Robert Young
University of California, Irvine